ValuEngine Upgrades Eyepoint Pharmaceuticals (EYPT) to “Buy”

Eyepoint Pharmaceuticals (NASDAQ:EYPT) was upgraded by analysts at ValuEngine from a “hold” rating to a “buy” rating in a report issued on Monday.

Several other research firms have also recently weighed in on EYPT. HC Wainwright set a $3.00 target price on shares of Eyepoint Pharmaceuticals and gave the company a “buy” rating in a research note on Thursday, August 2nd. B. Riley raised their target price on shares of Eyepoint Pharmaceuticals from $5.00 to $6.00 and gave the company a “buy” rating in a research note on Tuesday, October 16th. Finally, Zacks Investment Research raised shares of Eyepoint Pharmaceuticals from a “sell” rating to a “hold” rating in a research note on Tuesday, August 28th. One investment analyst has rated the stock with a sell rating and five have issued a buy rating to the stock. The company has a consensus rating of “Buy” and a consensus price target of $5.40.

Shares of EYPT opened at $2.14 on Monday. The company has a market cap of $119.95 million, a PE ratio of -3.69 and a beta of 0.83. Eyepoint Pharmaceuticals has a twelve month low of $0.93 and a twelve month high of $3.94. The company has a debt-to-equity ratio of 1.48, a current ratio of 1.84 and a quick ratio of 1.84.



Eyepoint Pharmaceuticals (NASDAQ:EYPT) last issued its quarterly earnings results on Wednesday, September 12th. The company reported ($0.19) earnings per share for the quarter, missing the consensus estimate of ($0.11) by ($0.08). The business had revenue of $0.72 million for the quarter, compared to the consensus estimate of $0.67 million. Eyepoint Pharmaceuticals had a negative return on equity of 301.45% and a negative net margin of 1,795.71%. As a group, sell-side analysts expect that Eyepoint Pharmaceuticals will post -0.42 EPS for the current fiscal year.

Several large investors have recently added to or reduced their stakes in EYPT. Renaissance Technologies LLC bought a new position in shares of Eyepoint Pharmaceuticals in the second quarter valued at $2,339,000. BlackRock Inc. bought a new position in shares of Eyepoint Pharmaceuticals in the second quarter valued at $304,000. Northern Trust Corp bought a new position in shares of Eyepoint Pharmaceuticals in the second quarter valued at $218,000. Bard Associates Inc. bought a new position in shares of Eyepoint Pharmaceuticals in the second quarter valued at $189,000. Finally, Essex Investment Management Co. LLC bought a new position in shares of Eyepoint Pharmaceuticals in the second quarter valued at $170,000. 63.00% of the stock is owned by institutional investors and hedge funds.

About Eyepoint Pharmaceuticals

EyePoint Pharmaceuticals, Inc, a specialty biopharmaceutical company, develops and commercializes ophthalmic products for the treatment of eye diseases. The company's lead product is ILUVIEN for the treatment of diabetic macular edema; and product candidate is YUTIQ, a non-erodible fluocinolone acetonide insert for the treatment of non-infectious posterior uveitis that is in the Phase III clinical trials.

Featured Story: What is a put option?

To view ValuEngine’s full report, visit ValuEngine’s official website.

Receive News & Ratings for Eyepoint Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Eyepoint Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply